Captopril in cardiological patients treatment: is there still place for the “first of the Mohicans”?

• Main Authors: Farogat Yu. Valikulova, Liubov Yu. Koroleva, Olesia V. Melnichenko, Elena M. Durygina, Fazliniso N. Muradova, Mariia M. Alekseeva
• Format: Article
• Language: Russian
• Published: ZAO "Consilium Medicum" 2019-01-01
• Series: Consilium Medicum
• Subjects: angiotensin-converting enzyme inhibitor; sulfhydryl group; captopril; hypertensive crisis; arterial hypertension; diabetes mellitus; myocardial infarction; congestive heart failure
• Online Access: http://consilium.orscience.ru/en/archive/2019/vol-21-1-2019/captopril-in-cardiological-patients-treatment-is-there-still-place-for-the-first-of-the-mohicans-_5102/?element
• ISSN: 2075-1753; 2542-2170

Aim. To demonstrate significance and relevancy of the first angiotensin-converting enzyme inhibitor (ACE inhibitor) captopril use in treatment of patients with cardiovascular disorders. Materials and methods. The article covers the issues of captopril use launch, results of the main randomized clinical studies of it, basic pharmacokinetic characteristics, and indications for captopril use from the perspective of the present clinical guidelines. Conclusion. The first oral ACE inhibitor captopril that was developed more than 40 years ago still holds a valuable place in treatment of cardiovascular diseases such as arterial hypertension, myocardial infarction, congestive heart failure and diabetes mellitus complications. Despite development of ACE inhibitors with longer duration of action and new properties, captopril still remains one of the most effective medications with a wide range of clinical use – from uncomplicated hypertensive crises arrest to long-term use in patients with arterial hypertension, diabetes mellitus, and congestive heart failure. Captopril remains one of the few ACE inhibitors that have changed approaches to treatment of patients with heart failure and improved the survival rate of patients after acute myocardial infarction.